KalVista Pharmaceuticals (NASDAQ:KALV) Sees Large Volume Increase – Here’s Why

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) saw an uptick in trading volume on Thursday . 2,962,606 shares traded hands during mid-day trading, an increase of 54% from the previous session’s volume of 1,921,224 shares.The stock last traded at $26.6750 and had previously closed at $26.67.

Key KalVista Pharmaceuticals News

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Chiesi agreed to acquire KalVista for approximately $1.9 billion in cash, agreeing to pay $27.00 per share — a definitive buyout that provides a guaranteed cash payout to public shareholders. Reuters: Italian drugmaker Chiesi to buy KalVista for $1.9 billion
• Positive Sentiment: Market response: multiple outlets report KalVista shares jumping roughly 38–39% on the buyout news and unusually high trading volume, reflecting investor acceptance of the cash premium. Investing.com: KalVista stock surges 39% on $1.9B Chiesi buyout
• Neutral Sentiment: Strategic rationale: Chiesi is buying KalVista primarily for its hereditary angioedema (HAE) drug Ekterly, expanding Chiesi’s rare-disease portfolio; that underpins the acquisition price but also places value on longer-term commercialization potential. BioPharmaDive: Chiesi to buy KalVista in $1.9B deal for rare disease drug
• Negative Sentiment: Shareholder litigation/inspections: law firms have launched investigations and potential class actions questioning whether the $27 per-share offer is fair, which could lead to litigation that delays closing or pressures terms. PR Newswire: Ademi LLP shareholder alert
• Negative Sentiment: Additional law-firm probe: another class-action firm (Monteverde & Associates) is investigating the transaction’s fairness; multiple suits could increase deal risk or lead to renegotiation/settlement costs. GlobeNewswire: Monteverde investigation notice

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on KALV. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. HC Wainwright boosted their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Stifel Nicolaus boosted their target price on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Citizens Jmp cut their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Thursday, March 26th. Finally, Needham & Company LLC upped their price objective on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.60.

KalVista Pharmaceuticals Stock Up 0.0%

The business has a 50-day moving average price of $18.24 and a two-hundred day moving average price of $15.64. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The firm has a market cap of $1.37 billion, a PE ratio of -6.75 and a beta of -0.40.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 5,354 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $83,361.78. Following the completion of the transaction, the insider owned 138,983 shares in the company, valued at $2,163,965.31. This represents a 3.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Nicole Sweeny sold 3,975 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $61,890.75. Following the completion of the transaction, the insider owned 47,003 shares of the company’s stock, valued at $731,836.71. This represents a 7.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 263,969 shares of company stock valued at $4,536,178 over the last ninety days. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several large investors have recently bought and sold shares of KALV. AQR Capital Management LLC acquired a new position in KalVista Pharmaceuticals in the first quarter valued at $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in KalVista Pharmaceuticals by 13.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock valued at $281,000 after acquiring an additional 2,939 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in KalVista Pharmaceuticals by 3.7% in the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company’s stock valued at $3,923,000 after acquiring an additional 12,263 shares in the last quarter. Creative Planning boosted its stake in KalVista Pharmaceuticals by 20.0% in the second quarter. Creative Planning now owns 33,380 shares of the specialty pharmaceutical company’s stock valued at $377,000 after acquiring an additional 5,573 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of KalVista Pharmaceuticals by 2.8% during the second quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after buying an additional 1,458 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.